MX2015000398A - Formulaciones de laquinimod sin agente alcalinizante. - Google Patents
Formulaciones de laquinimod sin agente alcalinizante.Info
- Publication number
- MX2015000398A MX2015000398A MX2015000398A MX2015000398A MX2015000398A MX 2015000398 A MX2015000398 A MX 2015000398A MX 2015000398 A MX2015000398 A MX 2015000398A MX 2015000398 A MX2015000398 A MX 2015000398A MX 2015000398 A MX2015000398 A MX 2015000398A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- multiple sclerosis
- stable pharmaceutical
- subject
- subject invention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670268P | 2012-07-11 | 2012-07-11 | |
| PCT/US2013/049894 WO2014011750A1 (en) | 2012-07-11 | 2013-07-10 | Laquinimod formulations without alkalizing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015000398A true MX2015000398A (es) | 2015-04-10 |
Family
ID=49914501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000398A MX2015000398A (es) | 2012-07-11 | 2013-07-10 | Formulaciones de laquinimod sin agente alcalinizante. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140018386A1 (https=) |
| EP (1) | EP2872141A4 (https=) |
| JP (1) | JP2015527321A (https=) |
| KR (1) | KR20150036553A (https=) |
| CN (1) | CN104470519A (https=) |
| AR (1) | AR091706A1 (https=) |
| AU (1) | AU2013290274A1 (https=) |
| BR (1) | BR112015000321A2 (https=) |
| CA (1) | CA2873230A1 (https=) |
| EA (1) | EA201590193A1 (https=) |
| HK (1) | HK1209054A1 (https=) |
| IL (1) | IL236229A0 (https=) |
| MX (1) | MX2015000398A (https=) |
| NZ (1) | NZ630241A (https=) |
| SG (2) | SG10201700198VA (https=) |
| TW (1) | TW201408299A (https=) |
| UA (1) | UA115555C2 (https=) |
| WO (1) | WO2014011750A1 (https=) |
| ZA (1) | ZA201500287B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| CN107823168A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种快速溶解的片剂及其制备方法 |
| CN107823150A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种可快速分散的片剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| ES2445451T3 (es) * | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| WO2013016686A1 (en) * | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
-
2013
- 2013-07-08 AR ARP130102429 patent/AR091706A1/es unknown
- 2013-07-09 TW TW102124610A patent/TW201408299A/zh unknown
- 2013-07-10 SG SG10201700198VA patent/SG10201700198VA/en unknown
- 2013-07-10 EA EA201590193A patent/EA201590193A1/ru unknown
- 2013-07-10 KR KR1020157003693A patent/KR20150036553A/ko not_active Withdrawn
- 2013-07-10 EP EP13816725.9A patent/EP2872141A4/en not_active Withdrawn
- 2013-07-10 BR BR112015000321A patent/BR112015000321A2/pt active Search and Examination
- 2013-07-10 MX MX2015000398A patent/MX2015000398A/es unknown
- 2013-07-10 HK HK15109818.4A patent/HK1209054A1/xx unknown
- 2013-07-10 JP JP2015521771A patent/JP2015527321A/ja active Pending
- 2013-07-10 AU AU2013290274A patent/AU2013290274A1/en not_active Abandoned
- 2013-07-10 CN CN201380027660.2A patent/CN104470519A/zh active Pending
- 2013-07-10 NZ NZ630241A patent/NZ630241A/en not_active IP Right Cessation
- 2013-07-10 SG SG11201407688QA patent/SG11201407688QA/en unknown
- 2013-07-10 WO PCT/US2013/049894 patent/WO2014011750A1/en not_active Ceased
- 2013-07-10 CA CA2873230A patent/CA2873230A1/en not_active Abandoned
- 2013-07-10 US US13/938,733 patent/US20140018386A1/en not_active Abandoned
- 2013-10-07 UA UAA201413984A patent/UA115555C2/uk unknown
-
2014
- 2014-12-14 IL IL236229A patent/IL236229A0/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00287A patent/ZA201500287B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ630241A (en) | 2017-09-29 |
| ZA201500287B (en) | 2016-10-26 |
| EA201590193A1 (ru) | 2015-04-30 |
| TW201408299A (zh) | 2014-03-01 |
| IL236229A0 (en) | 2015-01-29 |
| US20140018386A1 (en) | 2014-01-16 |
| EP2872141A4 (en) | 2016-01-13 |
| BR112015000321A2 (pt) | 2017-06-27 |
| SG11201407688QA (en) | 2014-12-30 |
| WO2014011750A1 (en) | 2014-01-16 |
| JP2015527321A (ja) | 2015-09-17 |
| EP2872141A1 (en) | 2015-05-20 |
| HK1209054A1 (zh) | 2016-03-24 |
| AR091706A1 (es) | 2015-02-25 |
| WO2014011750A8 (en) | 2014-12-04 |
| SG10201700198VA (en) | 2017-02-27 |
| AU2013290274A1 (en) | 2014-11-27 |
| KR20150036553A (ko) | 2015-04-07 |
| UA115555C2 (uk) | 2017-11-27 |
| CN104470519A (zh) | 2015-03-25 |
| CA2873230A1 (en) | 2014-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015000398A (es) | Formulaciones de laquinimod sin agente alcalinizante. | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| MX2015010296A (es) | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. | |
| MX2016004741A (es) | Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico. | |
| NZ630471A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| WO2014071168A3 (en) | Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients | |
| PH12014502079A1 (en) | Vesicular formulations for use in the treatment of pain or reduced mobility of a joint | |
| TN2016000005A1 (en) | Substituted pyrazolo-pyridinamines | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| MY171526A (en) | Pharmaceutical formulation for reducing frequency of urination and method of use thereof | |
| MX353580B (es) | Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel. | |
| IN2014DN09437A (https=) | ||
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| PH12015500070A1 (en) | Pediatric oral liquid compositions containing nepadutant | |
| MX2016003230A (es) | Complejo lubricante para la boca. | |
| UA109944U (uk) | Фармацевтична композиція для зниження рівня n-оксиду триметиламіну | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| MX2016003763A (es) | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. | |
| WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis | |
| MX2013006332A (es) | Composiciones farmaceuticas orales para uso en dislipidemias. | |
| MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |